Tivicay
/
Tivicay (dolutegravir) is an integrase strand transfer inhibitor used in the treatment of HIV-1 infection in adults and children. It is administered as an oral tablet and is available by prescription only. Patients are advised to be aware that Tivicay may cause serious side effects, including hypersensitivity reactions, and should not be used in individuals with a history of severe allergic reactions to dolutegravir or any of its components.
Pay securely with Zelle
FAQs about Tivicay
What should I do if I miss a dose?
If you miss a dose of Tivicay, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and resume your regular dosing schedule. Do not take two doses at the same time to make up for a missed dose. This information is provided in the Patient Counseling Information section of the label.
Can I take Tivicay while pregnant or breastfeeding?
The use of Tivicay during pregnancy should be discussed with your healthcare provider, as the benefits and risks must be carefully considered. It is also advised to consult your healthcare provider if you are breastfeeding, as it is not known if Tivicay passes into breast milk. This information is found in the Pregnancy and Lactation sections of the label.
Can I stop taking Tivicay suddenly?
It is not recommended to stop taking Tivicay suddenly without consulting your healthcare provider, as this may lead to a return of the virus. Your healthcare provider will guide you on how to safely discontinue the medication if necessary. This warning is included in the Warnings and Precautions section of the label.
How should I store Tivicay?
Tivicay should be stored at room temperature, between 20°C to 25°C (68°F to 77°F). Keep it in its original container and protect it from moisture and light. This storage information is detailed in the Storage section of the label.
25
commonly-prescribed
medication.
🍪 We use cookies
We use cookies to enhance your browsing experience, serve personalised content, and analyse traffic. By clicking "Accept all", you consent to our use of cookies.